ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cyclobenzaprine

Also written as “TNX-102 SL”, “TNX-102 SL 5.6 mg” and “Treatment A”.

Its studies are mostly in Fibromyalgia · Stress Disorders, Post-Traumatic · Depressive Disorder, Major · Post-Acute COVID-19 Syndrome · Neck Pain, led by 7 companies.

Drug pageCyclobenzaprine: every studyMany companies study it; this page follows only the 32 they lead. All 42 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 12, 201332 company-led studies, 2 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tonix Pharmaceuticals262 open or runningphase 3since Jul 12, 2013Dec 7, 2011Feb 2028phase 2 · NCT07621237
Eurofarma Laboratoriosits history only10 open or runningphase 3since Apr 24, 2012Apr 24, 2012none ahead
Johnson & Johnsonits history only10 open or runningphase 4since Oct 28, 2005Oct 28, 2005none ahead
Neurana Pharmaceuticalsits history only10 open or runningphase 1since Nov 14, 2017Nov 14, 2017none ahead
Novartisits history only10 open or runningphase 1since Jun 2, 2009Jun 2, 2009none ahead
Sun Pharmaceutical Industriesits history only10 open or runningno phasesince Oct 22, 2008Oct 22, 2008none ahead
Takedaits history only10 open or runningphase 3since Jun 23, 2016Jun 23, 2016none ahead

Also a collaborator on its studies: Altasciences, Premier Research Group and Cognitive Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Tonix Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Dec 7, 2011.

  1. Mar 31, 2017Phase 3 study in Stress Disorders, Post-TraumaticNCT03110575 · 190 enrolled · United States
  2. Apr 25, 2017Phase 1 study in Healthy AdultsNCT03168022 · 43 enrolled · Canada
  3. Feb 6, 2018Phase 1 study in Healthy SubjectsNCT03443960 · 60 enrolled · Canada
  4. Apr 12, 2018Phase 3 study in Stress Disorders, Post-TraumaticNCT03508700 · 93 enrolled · United States
  5. Feb 12, 2019Phase 3 study in Stress Disorders, Post-TraumaticNCT03841773 · 192 enrolled · United States
  6. Nov 13, 2019Phase 1 study in Healthy SubjectsNCT04164719 · 16 enrolled · Canada
  7. Nov 20, 2019Phase 3 study in FibromyalgiaNCT04172831 · 503 enrolled · United States
  8. Aug 7, 2020Phase 3 study in FibromyalgiaNCT04508621 · 514 enrolled · United States
  9. Mar 1, 2022Phase 3 study in FibromyalgiaNCT05273749 · 457 enrolled · United States
  10. May 9, 2022Phase 2 study in Stress Disorders, Post-TraumaticNCT05372887 · Kenya
  11. Jul 21, 2022Phase 2 study in InfectionsNCT05472090 · 63 enrolled · United States
  12. Jan 26, 2026Phase 1 study in PharmakokineticNCT07413367 · 50 enrolled · Canada
  13. Mar 6, 2026Phase 1 study in Healthy Subjects (HS)NCT07464535 · 20 enrolled · United States
  14. May 27, 2026Phase 2 study in Depressive Disorder, MajorNCT07621237 · 360 planned · United States

Ahead

  1. Feb 2028Primary completion: phase 2 study in Depressive Disorder, MajorNCT07621237

TargetBeta

HTR2A →HTR2C →read by rule
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
RisperidoneruleJohnson & Johnsonphase 4111
OlanzapineruleEli Lillyphase 476
TrazodoneruleAngelini Pharmaphase 314

Studies

All 26 Tonix Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07621237Depressive Disorder, Major · United States2RecruitingFeb 2028360
NCT07464535Healthy Subjects (HS) · United States1CompletedApr 30, 202220
NCT07413367Pharmakokinetic · Canada1Active, not recruitingFeb 10, 202650
NCT05472090Infections · United States2CompletedJul 12, 202363
NCT05372887Stress Disorders, Post-Traumatic · Kenya2WithdrawnNov 8, 20220
NCT05273749Fibromyalgia · United States3CompletedNov 14, 2023457
NCT04508621Fibromyalgia · United States3CompletedNov 1, 2021514
NCT04172831Fibromyalgia · United States3CompletedOct 29, 2020503
NCT04164719Healthy Subjects · Canada1CompletedDec 24, 201916
NCT03841773Stress Disorders, Post-Traumatic · United States3TerminatedApr 24, 2020192
NCT03508700Stress Disorders, Post-Traumatic · United States3CompletedSep 30, 201993
NCT03443960Healthy Subjects · Canada1CompletedApr 9, 201860
NCT03168022Healthy Adults · Canada1CompletedJan 26, 201643
NCT03110575Stress Disorders, Post-Traumatic · United States3TerminatedJul 27, 2018190
NCT03062540Stress Disorders, Post-Traumatic · United States3TerminatedJul 27, 2018358
NCT02829814Fibromyalgia · United States3TerminatedSep 13, 201651
NCT02589275Fibromyalgia · United States3CompletedSep 28, 2016375
NCT02436096Fibromyalgia · United States3CompletedSep 2016519
NCT02421679Stress Disorders, Post-Traumatic · United States2CompletedMay 26, 2016159
NCT02277704Stress Disorders, Post-Traumatic · United States2CompletedMay 2016245
NCT02015234Fibromyalgia · United States3CompletedAug 2015158
NCT01903265Fibromyalgia · United States3CompletedJul 2014205
NCT01889173Healthy Adults · Canada1CompletedDec 201324
NCT01689259Healthy Adults · Canada1CompletedDec 201324
NCT01634412Healthy Adults · Canada1CompletedSep 201324
NCT01490788Healthy · Canada1CompletedDec 30, 201130

How it is read

Names in the registry

  • “TNX-102 SL”, 13 entries
  • “TNX-102 SL 5.6 mg”, 2 entries
  • “Treatment A”, 2 entries
  • “Treatment B”, 2 entries
  • “TNX-102 SL Tablet”, 1 entry

Codes read as this program: TNX102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.